Total raised
$62.5M
Last: Series C 2020-12
Stage
Acquired
Founded
1999
Headcount
5
HQ
Lod
Sector
Health Tech & Life Sciences
About
Biosight is a phase-2 clinical-stage biotechnology company developing therapeutics for Hematological Malignancies and disorders.
Biosight's lead product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging phase-1/2a trial, which demonstrated tolerability with promising efficacy in AML patients unfit for standard therapy.
Funding history · 5 rounds · $62.5M total
2020-12
Series C
$27.0M
2020-03
Series C
$19.0M
2016-05
Series B
$13.0M
2008-07
Undisclosed
$3.5M
2007-01
Undisclosed
Undisclosed
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
chemotherapycancerdrug-discoverybiopharmaceuticaltargeted-therapypharmaceuticalscancer-therapyoncologyhematology